Royalderm Agnieszka Nawrocka

Warsaw 02962

4 studies enrolling now · 25 studies all time

What they study most

Alopecia, Alopecia Areata, Areata Alopecia, Atopic Dermatitis, Chronic Spontaneous Urticaria, Dermatitis, Atopic, Hair Diseases, Hidradenitis Suppurativa, Hypotrichosis, NonSegmental Vitiligo, Palmoplantar Pustulosis, Pathological Conditions, Anatomical

Studies at this site

• Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) — Recruiting now
• A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata — Recruiting now
• A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis — Recruiting now
• A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS. — Recruiting now
• A Study of JNJ-95475939 in the Treatment of Participants With Moderate to Severe Atopic Dermatitis (AD) — Stopped early
• A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis — Stopped early
• A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE) — Completed
• A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Stopped early
• A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2) — Running, not enrolling
• A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis — Running, not enrolling
• A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis — Completed
• A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2) — Running, not enrolling
• Long-Term PF-06651600 for the Treatment of Alopecia Areata — Completed
• A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) — Running, not enrolling
• A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria — Running, not enrolling
• A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) — Completed
• Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS) — Completed
• A Study to Learn How Well the Study Treatment Zabedosertib (BAY1834845) Works and How Safe it is Compared to Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis — Completed
• A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa — Stopped early
• A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP) — Stopped early
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) — Completed
• A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis — Stopped early
• PF-06651600 for the Treatment of Alopecia Areata — Completed
• A Study of Crisaborole Ointment 2%; Crisaborole Vehicle; TCS and TCI in Subjects Aged ≥ 2 Years, With Mild-moderate AD — Stopped early
• Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis — Completed